Families Left Behind
Families Left Behind: Addressing Prolonged Grief and Substance Use Disorders Among People Bereaved by Drug Overdose Deaths
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Karen Osilla, PhD
- Email: kosilla@stanford.edu
Study Contact Backup
- Name: Alison Athey, PhD
- Phone Number: 5680 (703) 413-1100
- Email: aathey@rand.org
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35203
- Recruiting
- Jefferson County Coroner/Medical Examiner's Office
-
Contact:
- Daniel Dye, MD
- Email: dwdye@uab.edu
-
-
California
-
San Diego, California, United States, 92123
- Recruiting
- San Diego County Medical Examiner Office
-
Contact:
- Jonathan Lucas, MD
- Email: jonathan.lucas@sdcounty.ca.gov
-
-
Connecticut
-
Farmington, Connecticut, United States, 06032
- Recruiting
- Connecticut Office of the Chief Medical Examiner
-
Contact:
- James Gill, MD
- Email: jgill@ocme.org
-
-
Massachusetts
-
Watertown, Massachusetts, United States, 02472
- Active, not recruiting
- Peer Support Community Partners
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- people who lost a loved one to an unintentional drug overdose death within the past year
- age 18 and older
- fluently understand English or Spanish
- have the capacity to give consent (e.g., excluding those with severe cognitive impairment, those in active psychosis, and those with developmental disabilities).
Exclusion Criteria:
- people who need hospitalization for psychiatric symptoms or substance use disorders. (Note, people who use drugs but who do not require hospitalization will be included.)
- people have active suicidal ideation
- people who lost someone to a drug overdose death more than one year ago
- people who lost someone to a drug overdose death that was suicidal in nature or of undetermined intent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Peer grief support + enhanced care as usual
Participants in this arm will be matched with a peer grief support specialist who will provide support that aligns with the RIVER process model developed by Peer Community Support Partners.
They will also receive a psychoeducational booklet and a list of local grief support resources (i.e., the enhanced care as usual condition).
|
RIVER is a peer grief support process intervention developed by Peer Support Community Partners.
The enhanced care as usual condition involves a psychoeducational booklet developed by What's Your Grief, as well as a list of local grief resources.
|
|
Active Comparator: Enhanced care as usual
Participants will receive a psychoeducational booklet and a list of local grief support resources.
|
The enhanced care as usual condition involves a psychoeducational booklet developed by What's Your Grief, as well as a list of local grief resources.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant Grief Symptoms
Time Frame: Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
Brief Grief Questionnaire; evaluates the presence of prolonged grief
|
Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
|
Participant Avoidance of Grief Reminders
Time Frame: Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
Grief-Related Avoidance Questionnaire (GRAQ); evaluating the presence and extent of avoidance behaviors due to feelings of grief
|
Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
|
Participant Bereavement Coping Strategies
Time Frame: Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
Coping Assessment for Bereavement (CABLE); evaluating what coping strategies are being utilized and at what frequency
|
Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
|
Participant Acceptance of the Loss
Time Frame: Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
Typical Beliefs Questionnaire (TBQ); evaluating the presence of maladaptive cognitions related to complicated grief
|
Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
|
Participant Perceived Connectedness
Time Frame: Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
Continuing Bonds Scale; assessing the extent to which the participant feels bonded to the descendent
|
Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant Substance Use
Time Frame: Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
Tobacco, Alcohol, Prescription Medications, and Other Substances Tool (TAPS); assessing the presence and frequency of past 30-day substance use
|
Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
|
Participant Depression Severity
Time Frame: Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
Beck Depression Inventory (BDI); evaluating the presence and severity of depressive symptoms
|
Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
|
Participant Posttraumatic Stress Symptoms
Time Frame: Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
Posttraumatic Stress Disorder Checklist (PCL-5); evaluating the severity of symptoms associated with posttraumatic stress disorder
|
Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
|
Participant Physical Pain Severity
Time Frame: Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
PEG; evaluating the intensity and interference of physical pain on daily life and well-being
|
Baseline, 3-month follow up, 6-month follow up, and 12-month follow up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Karen Osilla, PhD, Stanford University
- Principal Investigator: Alison Athey, PhD, RAND
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024-N0522
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.